JP6110817B2 - 大環状キナーゼ阻害剤の固体形態 - Google Patents

大環状キナーゼ阻害剤の固体形態 Download PDF

Info

Publication number
JP6110817B2
JP6110817B2 JP2014124999A JP2014124999A JP6110817B2 JP 6110817 B2 JP6110817 B2 JP 6110817B2 JP 2014124999 A JP2014124999 A JP 2014124999A JP 2014124999 A JP2014124999 A JP 2014124999A JP 6110817 B2 JP6110817 B2 JP 6110817B2
Authority
JP
Japan
Prior art keywords
ppm
crystalline
values
resonance
value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014124999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015010091A (ja
JP2015010091A5 (enExample
Inventor
ジェームス ジェンセン アンドリュー
ジェームス ジェンセン アンドリュー
ルスラ スマン
ルスラ スマン
フランシス リチャードソン ポール
フランシス リチャードソン ポール
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2015010091A publication Critical patent/JP2015010091A/ja
Publication of JP2015010091A5 publication Critical patent/JP2015010091A5/ja
Application granted granted Critical
Publication of JP6110817B2 publication Critical patent/JP6110817B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2014124999A 2013-06-28 2014-06-18 大環状キナーゼ阻害剤の固体形態 Active JP6110817B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840703P 2013-06-28 2013-06-28
US61/840,703 2013-06-28

Publications (3)

Publication Number Publication Date
JP2015010091A JP2015010091A (ja) 2015-01-19
JP2015010091A5 JP2015010091A5 (enExample) 2016-08-04
JP6110817B2 true JP6110817B2 (ja) 2017-04-05

Family

ID=51136530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014124999A Active JP6110817B2 (ja) 2013-06-28 2014-06-18 大環状キナーゼ阻害剤の固体形態

Country Status (8)

Country Link
US (1) US9637500B2 (enExample)
EP (1) EP3013835B1 (enExample)
JP (1) JP6110817B2 (enExample)
AR (1) AR096759A1 (enExample)
CA (1) CA2916605C (enExample)
ES (1) ES2656189T3 (enExample)
TW (1) TW201504246A (enExample)
WO (1) WO2014207606A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6609308B2 (ja) * 2014-08-20 2019-11-20 テリジーン リミテッド キナーゼ阻害剤としての置換マクロサイクル
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
MX382600B (es) 2015-07-31 2025-03-13 Pfizer Forma cristalina de base libre de lorlatinib.
WO2017058780A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
CN112920201A (zh) 2016-03-03 2021-06-08 深圳市塔吉瑞生物医药有限公司 一种大环化合物及包含该化合物的组合物
EP3770164A1 (en) 2016-04-08 2021-01-27 Pfizer Inc Crystalline forms of lorlatinib maleate
PT3694863T (pt) 2017-10-10 2023-08-23 Pfizer Forma cristalina do hidrato de base livre de lorlatinib
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
US20210163498A1 (en) 2018-04-23 2021-06-03 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
US12077528B2 (en) 2018-11-28 2024-09-03 Shenzhen Targetrx, Inc. Preparation method for deuterated macrocyclic compound
CN109651398B (zh) * 2019-01-25 2021-07-30 安庆多辉生物科技有限公司 一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法
EP3999514A1 (en) 2019-07-18 2022-05-25 Pliva Hrvatska D.O.O. Crystalline lorlatinib : fumaric acid and solid state form thereof
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
CN110483551B (zh) * 2019-08-30 2021-10-22 北京赛思源生物医药技术有限公司 一种劳拉替尼游离碱的晶体
WO2021069571A1 (en) 2019-10-10 2021-04-15 Sandoz Ag Polymorph of lorlatinib
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
US20230117684A1 (en) 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
CA3179700A1 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
CN112724077B (zh) * 2020-12-29 2023-07-11 武汉利昌医药科技有限公司 一种劳拉替尼中间体的合成方法
CN113292496B (zh) * 2021-05-17 2023-03-10 安徽联创生物医药股份有限公司 一种劳拉替尼中间体的合成方法
WO2023056405A1 (en) 2021-10-01 2023-04-06 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
PE20142339A1 (es) 2012-03-06 2015-01-15 Pfizer Derivados macrociclicos para el tratamiento de enfermedades

Also Published As

Publication number Publication date
US20160115178A1 (en) 2016-04-28
CA2916605A1 (en) 2014-12-31
JP2015010091A (ja) 2015-01-19
CA2916605C (en) 2018-04-24
EP3013835A1 (en) 2016-05-04
AR096759A1 (es) 2016-02-03
ES2656189T3 (es) 2018-02-26
WO2014207606A1 (en) 2014-12-31
EP3013835B1 (en) 2017-12-13
US9637500B2 (en) 2017-05-02
TW201504246A (zh) 2015-02-01

Similar Documents

Publication Publication Date Title
JP6110817B2 (ja) 大環状キナーゼ阻害剤の固体形態
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
KR102088188B1 (ko) 롤라티닙 유리 염기의 결정질 형태
KR102516745B1 (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
EP3173412B1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
CA3019905C (en) Crystalline forms of lorlatinib maleate
AU2016288209B2 (en) Crystalline fumarate salt of (S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl) (3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl)-methanone
KR20210104808A (ko) Tgfb 억제제의 신규한 다형체 형태
KR20100085142A (ko) Ｃ-ｍｅｔ/ｈｇｆｒ 억제제의 다형체
JP2023502857A (ja) Ｌｒｒｋ２阻害薬としてのｎ－（ヘテロアリール）キナゾリン－２－アミン誘導体、医薬組成物及びその使用
JP2007277241A (ja) （２Ｒ，Ｚ）−２−アミノ−２−シクロヘキシル−Ｎ−（５−（１−メチル−１Ｈ−ピラゾール−４−イル）−１−オキソ−２，６−ジヒドロ−１Ｈ−［１，２］ジアゼピノ［４，５，６−ｃｄ］インドール−８−イル）アセトアミドの多形体
WO2021050580A1 (en) Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
JP7618575B2 (ja) Ｎ－（５－（（４－エチルピペラジン－１－イル）メチル）ピリジン－２－イル）－５－フルオロ－４－（３－イソプロピル－２－メチル－２ｈ－インダゾール－５－イル）ピリミジン－２－アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用
CN116535423B (zh) 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用
WO2024245364A1 (en) Solid forms of a macrocyclic farnesyltransferase inhibitor and formulations thereof, and methods of preparing and using the macrocyclic compound and its solid forms
WO2024153249A1 (zh) 作为pkmyt1抑制剂的化合物
TW202328152A (zh) 氮雜內醯胺化合物之晶型
CN120187724A (zh) 杂芳基衍生物化合物、及其用途
HK40064763A (en) Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170310

R150 Certificate of patent or registration of utility model

Ref document number: 6110817

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250